EMA Pharmacovigilance Risk Assessment Committee recommends restrictions on Protelos (Servier) as a treatment for Osteoporosis

 The FDA has approved trastuzumab-strf (HLX02; Hercessi), a trastuzumab (Herceptin) biosimilar as adjuvant therapy for patients with HER2-overexpressing breast cancer, and as treatment for patients with HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be switched to direct-acting oral anticoagulants (DOAC).